Factor in Medical Technology

deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke

REYKJAVIK, Iceland, July 13 /PRNewswire-FirstCall/ -- Scientists at deCODE genetics (Nasdaq: DCGN ) and colleagues from Europe and the United States today report the discovery of a common single-letter variant in the sequence of the human genome (SNP) conferring increased risk of atrial fibr...

Scientists Discover a Role for the Growth Factor TGF-beta in Maintaining Health of Retinal Blood Vessels

BOSTON, April 7 /PRNewswire-USNewswire/ -- Scientists at Schepens Eye Research Institute have found that the growth factor known as TGF-beta is essential to the health of blood vessels in the retina and that blocking it can cause retinal dysfunction. These findings, published in the April 2 is...

New Research Suggests Platelet 'Stickiness' May be the Single Most Important Risk Factor in Patients Treated with Coronary Stents - Findings May be Applicable to Anyone with Vascular Disease

BALTIMORE, Jan. 27 /PRNewswire/ -- Most Americans know their cholesterol level, but do they know how "sticky" their platelets are? Research findings from Dr. Paul A. Gurbel, an interventional cardiologist and Director of the Sinai Center for Thrombosis Research based at Sinai Hospital of Baltimor...

New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation

SAN FRANCISCO, Dec. 7 /PRNewswire-FirstCall/ -- Patients with non-valvular atrial fibrillation receiving either 30 mg or 60 mg once-daily dose of DU-176b, an investigational oral Factor Xa inhibitor, experienced comparable safety and tolerability compared to those taking warfarin, according to new...

Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation

TOKYO and EDISON, N.J., Dec. 7 /PRNewswire-FirstCall/ -- Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it has initiated its pivotal Phase III trial for DU-176b, an investigational oral Factor Xa inhibitor, in patients with atrial fibrillation. DU-176b is being developed solely...

Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483

SUNNYVALE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC ) today announced that the company has completed a Phase 1 clinical trial with PCI-27483, the company's novel, first-in-class small-molecule Factor VIIa inhibitor. The trial was conducted in sixteen (16) healt...

Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b

MUNICH, Germany, Sept. 2 /PRNewswire-FirstCall/ -- Data presented today at the Annual Congress of the European Society of Cardiology showed that the investigational oral Factor Xa inhibitor DU-176b reduced the incidence of venous thromboembolism (VTE) compared with dalteparin among patients un...

Senesco Chooses VGXI to Produce Factor 5A Plasmid

NEW BRUNSWICK, N.J., July 3 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT ) announced today that it has contracted with VGXI, Inc. (The Woodlands, TX) ("VGXI") to supply the plasmid portion of the Company's combination therapy consisting of the F...

Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia

SOUTH SAN FRANCISCO, Calif., May 6 /PRNewswire/ -- Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase(TM) therapeutics, announced that it has selected CB 813, an improved, second-generation variant of human coagulation factor VIIa, ...

Pharmacyclics' Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer

SAN DIEGO and SUNNYVALE, Calif., April 16 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC ) today presented preclinical results demonstrating the anti-tumor activity of PCI-27483, the company's small-molecule Factor VIIa inhibitor. The data were presented during the Annual Meeting...

Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease

BOSTON, Feb. 5 /PRNewswire-USNewswire/ -- A new study led by researchers at Joslin Diabetes Center has identified insulin resistance in the liver as a key factor in the cause of metabolic syndrome and its associated atherosclerosis, disorders that put tens of millions of Americans at high risk...

Baxter Announces Recombinant Factor IX Development Program For Hemophilia B

DEERFIELD, Ill., Jan. 7 /PRNewswire-FirstCall/ -- Baxter International Inc. (NYSE: BAX ) announced today that it has initiated pre-clinical programs to develop recombinant Factor IX proteins to treat hemophilia B. Baxter will develop both an unmodified recombinant Factor IX therapy for treatm...

Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B

LAGUNA NIGUEL, Calif., Nov. 13 /PRNewswire/ -- Inspiration Biopharmaceuticals announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin clinical trials with IB1001, an intravenous recombinant Factor IX (rFIX) produ...

New Risk Factor for Heart Disease Identified in Very Young Children, According to Study at American Heart Association Scientific Sessions

Cincinnati Children's Researcher Says 'Body Mass Index (BMI) Rebound Age' Can Predict Heart Disease and Calls for Pediatricians To Begin Measuring Children's BMI As Early as Age 3 ORLANDO, Fla., Nov. 5 /PRNewswire/ -- The results from the newest study in a continuum of rese...

deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack

REYKJAVIK, Iceland, Oct. 11 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN ) today announced the launch of deCODE MI(TM), a reference laboratory test for variations in the genome (called SNPs) that the company has associated with increased risk of myocardial infarction, or heart atta...

It's Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer

PARAMUS, N.J., Sept. 11 /PRNewswire-USNewswire/ -- If you have or have ever had chronic heartburn, you may be at risk for Barrett's esophagus, a serious complication of chronic, severe gastroesophageal reflux disease (GERD). Barrett's esophagus has been recognized as a major risk factor for de...

Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis

SAN FRANCISCO, July 10, 2007 /PRNewswire/ -- Portola Pharmaceuticals, Inc. announced positive Phase II data on its lead compound, PRT054021, an oral Factor Xa inhibitor, today at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Geneva, Switzerland. The EXPERT t...

Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent

Results Highlighted in Oral Presentation at International Symposium of Thrombosis and Haemostasis GENEVA, July 10, 2007 /PRNewswire-FirstCall/ -- Baxter Healthcare Corporation today announced the presentation of findings from the ADAPT (Analysis of Data from ADVATE(R) Prospective Trials) study pro...

Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis

HORSHAM, Pa.--(BUSINESS WIRE)--Jul 11, 2007 - Neose Technologies, Inc. (Nasdaq GM:NTEC) today announced that two poster presentations were presented with its collaborative partner, Novo Nordisk A/S, relating to GlycoPEGylated recombinant Factor VIIa at the XXIst Congress of the International Societ...

Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program

...very technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine , a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activit...

Study Results Show That Minimally Invasive Therapy is Successful for Over Two-Thirds of Stroke Patients Treated Outside the Standard Eight-Hour Window

...usetts General Hospital -- Harvard Medical School, presentation beyond eight hours of symptom onset has traditionally been the single most important factor in excluding patients from stroke treatment. Thus, continued Nogueira, when brain imaging studies revealed that a significant number of late-prese...

Estrogen Getting Cool Reception From Dermatologists for Mixed Results in Improving Appearance of Skin

...illers, to name a few. "The best advice I can offer my patients to improve their overall skin health is to wear sunscreen with a sun protection factor (SPF) of at least 30, don't smoke and use a topical retinoid," said Dr. Parsons. "When it comes to minimizing the cumulative effects of sun damage, an...

Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy

...noma were injected with a vaccine that included each patient's own immune cells (dendritic cells) and 500 micrograms of granulocyte-colony stimulating factor (GM-CSF), an immune stimulator, three times a week and then monthly for five months for a total of up to eight injections. The patient's dendritic cel...

Injection Reverses Heart-Attack Damage

... G rowth factor enhances heart regeneration, improves heart function without need for c...ital heart defects. In the July 24 issue of Cell , they show that a growth factor called neuregulin1 (NRG1), which is involved in the initial development of ...

FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent

...ficant blood pressure reductions, compared to taking either drug alone." Hypertension affects nearly 74 million US adults and is a major risk factor for cardiovascular disease, the number one leading cause of death in the US. If left untreated, patients with high blood pressure are at risk for card...

Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease

...uggests that the carriers of a common genetic risk factor for Alzheimer's disease begin to have memory decli...copies of the APOE e4 gene, the major genetic risk factor for developing Alzheimer's disease at older ages. ...ich they are accelerated by the major genetic risk factor for Alzheimer's disease," said Eric Reiman, M.D., ...

Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing

...tudy(1) with edoxaban(2) - an investigational oral factor Xa inhibitor - provides insights into why patients...b, is an oral anticoagulant that directly inhibits factor Xa, a clotting factor in the blood. Daiichi Sankyo is developing edoxab...

PTSD Associated With Higher Alzheimer's/Dementia Risk; Moderate Alcohol Consumption May Lower it

...ectly indicated no association between Alzheimer's and obesity or high blood pressure. Sixty-six percent (66%) did not know that high stress is a risk factor for dementia, and 34% did not know that physical exercise is a protective factor. On the positive side, nearly all study participants (94%) ...

Is Obesity an Oral Bacterial Disease?

...nces relevant to dentistry and the oral cavity and associated structures in health and disease. At 3.966, the JDR holds the highest Five-Year Impact factor of all dental journals publishing original research, with a cited half-life >10 years, reflecting the influential nature of the Journal 's content...

Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis

...very technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine , a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activit...

deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia

...y an important role in regulating both memory and cognition, processes that are often perturbed in schizophrenics. Another SNP is in the transcription factor 4 (TCF4) gene on chromosome 18, which is involved in brain development. Five of the SNPs are located very closely together in the Major Histocompatibi...

AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain

...read use, the IV PCA architecture has several limitations. The IV line tethering the patient to the PCA pump discourages mobility, which is a critical factor in preventing post-operative complications and advancing recovery. Furthermore, the invasive nature of the IV delivery mode poses infection risk as we...

SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

...rapy." Upon receipt of the corresponding Commission Decision, SIMPONI will be the first and only once-monthly subcutaneous anti-tumor necrosis factor (TNF) alpha therapy approved in Europe for the simultaneous treatment of RA, PsA, and AS. SIMPONI will be available in two device forms, either throug...

Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health (CDRH)

...isticians usually need to write special programs to verify the operating characteristics of each Bayesian submission separately. This is an inhibiting factor and puts considerable burden on sponsors in carrying out the simulations that are submitted to CDRH and on CDRH statisticians in validating what is su...

Cordex Signs European Development Partnership for ATPotent(TM) Sperm Motility Drug

...dex will have access to the clinical data to be obtained in this study to support the development of ATPotent(TM) in the rest of the world. Male factor infertility is implicated in about half of the six million infertile couples in the United States. Lack of, or low sperm motility or movement, is a co...

Value of Genetic Testing for Preventing Blood Clots Unproven, According to New AHRQ Study

...of JAMA , also failed to find any benefit from genetic testing of family members of patients who have at least one of the two mutations -- known as factor V Leiden (FVL) and prothrombin G20210A -- as well as a history of deep-vein thrombosis. As many as 600,000 Americans each year may have deep-v...

CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders

... --Orally Active Enhancer of Human Nerve Growth factor Has Demonstrated Promising Activity Preclinically-...ve agent that enhances the effects of nerve growth factor (NGF). CeNeRx intends to initiate a Phase l trial...ropathy (CIPN) later this year. "Nerve growth factor has long been of interest as a potential therapy f...

Scottsdale Facility to Be First in U.S. to Showcase True REST Technology

...on, Pain Relief and Improved Sleep Patterns SCOTTSDALE, Ariz., June 16 /PRNewswire/ -- According to the American Medical Association, stress is a factor in more than 75 percent of illness today. The World Health Organization cites stress as America's No. 1 Health Problem. And the American Psychological...

When It Comes to Natural Remedies for Hormonal Balance, the Proof Is in the Clinical Research

...ormones affect a woman's mood and cognitive function, they directly affect a woman's bone density, and hormones are without a doubt the most important factor of a woman's cardiovascular health," explains James Frame, CEO of Natural Health International (NHI), a vertically integrated San Francisco based heal...

New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients

...ed that a greater proportion of patients with moderately to severely active rheumatoid arthritis (RA) who had prior treatment with anti-tumor necrosis factor (TNF)-alpha agents and received subcutaneous injections of SIMPONI(TM) (golimumab) once every four weeks experienced significant improvements in signs...